Drug intelligence / Profile preview

bisacodyl + simeticone

Development stage
Phase 3
Lead developer
Boehringer Ingelheim
Modality
Small Molecules
Administration
Oral
01

Overview

Bisacodyl + simeticone is a fixed-dose combination therapy designed to address both constipation and the associated symptom of bloating. Bisacodyl is a diphenylmethane derivative stimulant laxative that acts directly on the colonic mucosa to stimulate sensory nerve endings, thereby increasing peristalsis and promoting bowel movements. Simeticone (also known as simethicone) is an orally administered anti-foaming agent that acts mechanically by reducing the surface tension of gas bubbles in the gastrointestinal tract, allowing them to coalesce and be passed more easily. This combination provides a dual-action approach: bisacodyl offers overnight relief from constipation, while simeticone provides immediate relief from gas-related discomfort and bloating. The combination has been evaluated in clinical trials (such as NCT02211976) and is typically used in over-the-counter (OTC) gastrointestinal products.

Brand names
Dulcolax Bloating ReliefDulcolax Multi-Symptom
Other names
bisacodyl and simeticonebisacodyl and simethiconebisacodyl + simethicone
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on bisacodyl + simeticone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bisacodyl + simeticone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call